These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21279815)

  • 1. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.
    Wick W; Wick A; Weiler M; Weller M
    Curr Neurol Neurosci Rep; 2011 Jun; 11(3):305-12. PubMed ID: 21279815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab does not increase the risk of remote relapse in malignant glioma.
    Wick A; Dörner N; Schäfer N; Hofer S; Heiland S; Schemmer D; Platten M; Weller M; Bendszus M; Wick W
    Ann Neurol; 2011 Mar; 69(3):586-92. PubMed ID: 21446027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.
    Burger MC; Mildenberger IC; Wagner M; Mittelbronn M; Steinbach JP; Bähr O
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
    Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
    J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
    Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
    J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
    Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
    Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
    Vredenburgh JJ; Cloughesy T; Samant M; Prados M; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Das A; Friedman HS
    Oncologist; 2010; 15(12):1329-34. PubMed ID: 21147867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic therapies for high-grade glioma.
    Norden AD; Drappatz J; Wen PY
    Nat Rev Neurol; 2009 Nov; 5(11):610-20. PubMed ID: 19826401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.
    Tamura R; Tanaka T; Miyake K; Yoshida K; Sasaki H
    Brain Tumor Pathol; 2017 Apr; 34(2):62-77. PubMed ID: 28386777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.
    Zhang W; Fulci G; Buhrman JS; Stemmer-Rachamimov AO; Chen JW; Wojtkiewicz GR; Weissleder R; Rabkin SD; Martuza RL
    Mol Ther; 2012 Jan; 20(1):37-45. PubMed ID: 21915104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].
    Tabatabai G; Stupp R
    Nervenarzt; 2010 Aug; 81(8):936-9. PubMed ID: 20669004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy.
    Fraum TJ; Kreisl TN; Sul J; Fine HA; Iwamoto FM
    J Neurooncol; 2011 Nov; 105(2):281-9. PubMed ID: 21603965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic Therapy of High-Grade Gliomas.
    Jo J; Wen PY
    Prog Neurol Surg; 2018; 31():180-199. PubMed ID: 29393186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
    Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
    Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.
    Hofer S; Elandt K; Greil R; Hottinger AF; Huber U; Lemke D; Marosi C; Ochsenbein A; Pichler J; Roelcke U; Weder P; Zander T; Wick W; Weller M
    Acta Oncol; 2011 Jun; 50(5):630-5. PubMed ID: 21495907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors.
    Goldlust SA; Cavaliere R; Newton HB; Hsu M; Deangelis LM; Batchelor TT; Gilbert MR; Lassman AB
    J Neurooncol; 2012 Apr; 107(2):407-11. PubMed ID: 22203237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.